In the Claims:

1. (Previously Presented) A compound of formula (I)



(I)

wherein:

R is halogen or C_{1-4} alkyl;

R_1 is hydrogen or C_{1-4} alkyl;

R_2 is hydrogen , C_{1-4} alkyl or R_2 together with R_3 represents C_{3-7} cycloalkyl;

R_3 is hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl or C_{3-6} alkenyl; or R_1 and R_3 together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group;

R_4 is trifluoromethyl, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethoxy or halogen;

R_5 is hydrogen and R_6 is NR_7R_8 or R_5 is NR_8R_9 and R_6 is hydrogen;

R_7 is hydrogen or C_{1-4} alkyl or R_7 and R_8 together with nitrogen to which they are attached are a saturated 5 to 7 membered heterocyclic group containing oxygen;

R_8 is hydrogen, phenyl, C_{3-7} cycloalkyl, $(CH_2)_pC(O)NR_{10}R_{11}$, a saturated 5 to 7 membered heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C_{1-4} alkyl, $S(O)_2C_{1-4}$ alkyl or $C(O)C_{1-4}$ alkyl, a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C_{1-4} alkyl $S(O)_2C_{1-4}$ alkyl or $C(O)C_{1-4}$ alkyl or R_8 represents a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms and optionally substituted by C_{1-4} alkyl, $S(O)_2C_{1-4}$ alkyl or $C(O)C_{1-4}$ alkyl; or R_8 is a C_{1-6} alkyl group optionally substituted by one or two groups selected from fluorine, phenyl(optionally substituted by C_{1-4} alkyl, $C(O)C_{1-4}$ alkyl or halogen), =O, C_{3-7} cycloalkyl, hydroxy, amino, dimethylamino, aminocarbonyl, C_{1-4} alkoxy or trifluoromethyl;

R_9 is hydrogen, C_{1-4} alkyl or R_9 and R_8 together with nitrogen to which they are attached are a 5 to 7 membered heterocyclic group optionally containing another heroatom selected from oxygen, sulphur and nitrogen and optionally substituted by one or two groups selected from C_{1-4} alkyl, =O, $S(O)_2C_{1-4}$ alkyl, $C(O)C_{3-7}$ cycloalkyl or $C(O)C_{1-4}$ alkyl;

R_{10} and R_{11} are independently hydrogen or C_{1-4} alkyl group;

X is a nitrogen atom and Y is CH or X represents CH and Y is nitrogen;

m is zero or an integer from 1 to 3;

n is an integer from 1 to 3;

p is zero, 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Previously Presented) A compound as claimed in claim 1 wherein R_6 is NR_7R_8 and R_5 is hydrogen, Y is nitrogen and X is CH.

3. (Previously Presented) A compound as claimed in claim 1 wherein m is zero or an integer from 1 to 2.

4. (Previously Presented) A compound as claimed in claim 1 wherein R_1 is a methyl group.

5. (Previously Presented) A compound as claimed in claim 1 wherein R_2 is a hydrogen atom or a methyl group.

6. (Previously Presented) A compound as claimed in claim 1 wherein R_3 is a hydrogen atom or a methyl group.

7. (Previously Presented) A compound as claimed in claim 1 wherein R_4 is a trifluoromethyl group and/or halogen and n is 2.

8. (Previously Presented) A compound as claimed in claim 1 wherein R_5 is hydrogen, $NH(C_{3-7}$ cycloalkyl), $NH(C_{1-4}$alkylC_{3-7} cycloalkyl), 1-piperazinyl(optionally substituted by one or two groups selected from C_{1-4} alkyl, =O, $S(O)_2C_{1-4}$ alkyl,

$C(O)C_{3-7}$ cycloalkyl or $C(O)C_{1-4}$ alkyl; piperidyl (optionally substituted by one or two groups selected from C_{1-4} alkyl, =O,) or morpholino.

9. (Previously Presented) A compound as claimed in claim 1 wherein R_6 is hydrogen, $N(C_{1-6}alkyl)_2$, $NH(C_{1-6}alkyl)$, $NH(CH_2)_pC(O)NR_{10}R_{11}$ wherein p is 1 or 2 and R_9 and R_{10} are independently hydrogen or methyl, $NH(C_{1-6}$ alkyltrifluoromethyl), $NH(C_{1-6}alkylC_{1-4}alkoxy)$, $NH(C_{1-6}alkylfluorine)$, $N(C_{1-6}$ alkyl)(C_{1-6} alkylfluorine), $NH(C_{1-6}$ alkylphenyl), $NH(C_{3-7}cycloalkyl)$, NH(piperidyl), NH (C_{1-6} alkyl aminocarbonyl), $NH(C_{1-6}$ alkyl-1.3 dioxolan-yl) or morpholino.

10. (Currently Amended) A compound as claimed in claim 1 wherein
R_6 is NR_7R_8 and R_5 is hydrogen, Y is nitrogen and X is CH or wherein R_6 is hydrogen and R_5 is NR_8R_9, Y is CH and X is nitrogen;
R_7 is hydrogen or methyl; R_8 is methyl, ethyl, dimethylpropyl, cyclopropyl, cyclobutyl, $CH_2C(O)NH_2$, piperidinyl, 1-methyl-piperidinyl, methyl substituted by a group selected from phenyl, cyclopropyl, 4-acetyl-piperazino, fluorine, methoxy, trifluoromethyl and 1.3 dioxolan-yl;
R_9 is hydrogen or methyl;
R_9 and R_8 together with nitrogen to which they are attached is 1-piperazinyl, acetyl-1-piperazinyl, morpholino;
R_7 and R_8 together with nitrogen to which they are attached is morpholino;
R is independently fluorine or methyl;
R_4 is trifluoromethyl and/or chlorine;
m is 1 or 2; and
n is 2.

11. (Previously Presented) A compound as claimed in claim 1 selected from : 4-(S)-Dimethylamino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide hydrochloride; 4-(S)-Dimethylamino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride; 4-(S)-(2-Fluoroethyl)-amino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis)-trifluoromethyl-phenyl)-ethyl]-methylamide hydrochloride; and 4-(S)-(2-Fluoro-

ethylamino)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride.

12-14. (Canceled).

15. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in a mixture with one or more pharmaceutically acceptable carriers or excipients.

16. (Canceled).

17. (Previously Presented) A process for the preparation of a compound as claimed claim 1 comprising reductive N-alkylation of a compound of formula (II), wherein R_{12} is =O and R_{13} is hydrogen or R_{12} is hydrogen and R_{13} is =O



(II)

NR_5R_6

(III)

with an amine derivative (III) or a salt thereof in the presence of a suitable metal reducing agent, followed where necessary or desired by one or more of the following steps:

i) removing any protecting group;

ii) isolating the compound as a salt or a solvate thereof;

iii) separating the compound into enantiomers thereof.

18. (Previously Presented) A compound as claimed in claim 1, wherein R_6 is hydrogen and R_5 is NR_8R_9, Y is CH and X is nitrogen.

19. (Previously Presented) A method for the treatment of a condition mediated by a tachykinin in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

20. (Previously Presented) The method as claimed in claim 19, wherein said tachykinin is substance P.

21. (Previously Presented) The method as claimed in claim 19, wherein said mammal is man.

22. (Previously Presented) A method for the treatment of a CNS disorder in a man comprising administering an effective amount of a compound as claimed in claim 1.

23. (Previously Presented) The method according to claim 22, wherein said CNS disorder is selected from depressive states and anxiety.

24. (Previously Presented) A method for the treatment of emesis in a mammal comprising administering an effective amount of a compound as claimed in claim 1.